AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Editas Medicine Inc (NASDAQ:EDIT)
1.9598 USD
+0.160 8.878%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.8 |
|---|---|
| Change | +0.160 8.878% |
| 52 W H/L (in USD) | 11.910/4.910 |
| EBITDA (in USD) | -179.282M |
| PE Ratio | -- |
| Volume | 1757014 |
| Diluted Eps TTM | -2.07 |
| Total Assets (in USD) | 499.153M |
|---|---|
| Total Liabilities (in USD) | 150.056M |
| Revenue TTM (in USD) | 69.407M |
| Cash (in USD) | 123.652M |
| Market Cap (in USD) | 453.946 M |
| Revenue Per Share TTM | 0.876 |
| Gross Profit TTM (in USD) | -155.246M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Employees: 265
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. James C. Mullen | Exec. Chairman | 1959 |
| 2. | Ms. Michelle Robertson | CFO, Principal Accounting Officer, Treasurer & Assistant Sec. | 1967 |
| 3. | Dr. Mark S. Shearman | Exec. VP & Chief Scientific Officer | 1960 |
| 4. | Dr. Bruce E. Eaton Ph.D. | Exec. VP & Chief Bus. Officer | 1954 |
| 5. | Dr. Gilmore O'Neill | Pres & CEO | 1964 |
| 6. | Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member | NA |
| 7. | Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member | 1954 |
| 8. | Dr. J. Keith Joung M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member | NA |
| 9. | Dr. David R. Liu Ph.D. | Co-Founder & Scientific Advisory Board Member | NA |
| 10. | Mr. Harry R. Gill III | Sr. VP of Operations | 1961 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -153.219M | -220.432M | -192.502M | -115.976M | -133.746M |
| Minority Interest | - | - | - | - | - |
| Net Income | -153.219M | -204.352M | -185.107M | -109.412M | -123.466M |
| Selling General Administrative | 69.653M | 70.704M | 76.183M | 67.576M | 64.555M |
| Gross Profit | 72.059M | 19.712M | 25.544M | 90.732M | -76.367M |
| Reconciled Depreciation | 6.175M | 6.337M | 5.053M | 3.959M | 2.83M |
| Ebit | -169.181M | -225.95M | -193.146M | -134.84M | -140.922M |
| Ebitda | -163.117M | -219.613M | -188.093M | -130.881M | -141.059M |
| Depreciation And Amortization | 6.064M | 6.337M | 5.053M | 3.959M | -0.137M |
| Operating Income | -169.181M | -225.95M | -193.146M | -134.84M | -140.922M |
| Other Operating Expenses | 247.304M | 245.662M | 218.69M | 225.572M | 161.453M |
| Interest Expense | - | 4.225M | 5.697M | 2.605M | 7.313M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 13.883M | 4.225M | 2.342M | 2.605M | 7.313M |
| Net Interest Income | 13.883M | 4.225M | 2.342M | 2.605M | 7.313M |
| Income Tax Expense | - | -16.08M | -7.395M | -6.564M | -10.28M |
| Total Revenue | 78.123M | 19.712M | 25.544M | 90.732M | 20.531M |
| Total Operating Expenses | 241.24M | 245.662M | 218.69M | 225.572M | 161.453M |
| Cost Of Revenue | 6.064M | 6.337M | 5.053M | 157.996M | 96.898M |
| Total Other Income Expense Net | 15.962M | 5.518M | 0.644M | 18.864M | 7.176M |
| Net Income From Continuing Ops | -195.083M | -220.432M | -192.502M | -115.976M | -133.746M |
| Net Income Applicable To Common Shares | - | -220.432M | -192.502M | -115.976M | -133.746M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 499.153M | 514.321M | 677.483M | 572.602M | 508.885M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 7.531M | 7.335M | 7.198M | 10.929M | 6.286M |
| Total Liab | 150.056M | 153.641M | 123.841M | 179.016M | 246.448M |
| Total Stockholder Equity | 349.097M | 360.68M | 553.642M | 393.586M | 262.437M |
| Other Current Liab | 34.563M | 31.296M | 20.192M | 24.046M | 24.802M |
| Common Stock | 0.008M | 0.007M | 0.007M | 0.006M | 0.005M |
| Capital Stock | 0.008M | 0.007M | 0.007M | 0.006M | 0.005M |
| Retained Earnings | -1231.35M | -1078.131M | -857.699M | -665.197M | -549.221M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 5.253M | 6.811M | 4.703M | 1.726M |
| Cash | 123.652M | 141.522M | 203.519M | 139.682M | 238.183M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 63.217M | 60.11M | 46.884M | 58.208M | 59.963M |
| Current Deferred Revenue | 8.221M | 8.221M | 11.333M | 20.943M | 23.514M |
| Net Debt | -87.116M | -97.576M | -177.141M | -113.547M | -209.102M |
| Short Term Debt | 12.164M | 11.082M | 10.309M | 6.811M | 5.804M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 36.536M | 43.946M | 26.378M | 26.135M | 29.081M |
| Other Stockholder Equity | 1580.241M | 1442.405M | 1411.827M | 1058.823M | 811.546M |
| Property Plant Equipment | - | 15.569M | 17.118M | 14.02M | 39.648M |
| Total Current Assets | 340.829M | 356.754M | 507.31M | 419.087M | 463.844M |
| Long Term Investments | 104.024M | 93.097M | 120.071M | 109.664M | 3.667M |
| Short Term Investments | 199.459M | 202.752M | 296.326M | 262.428M | 218.957M |
| Net Receivables | 10.187M | 5.145M | 0.267M | 6.048M | 0.418M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -93.097M | -120.07M | -109.664M | - |
| Accounts Payable | 8.269M | 9.511M | 5.05M | 6.408M | 5.843M |
| Accumulated Other Comprehensive Income | 0.198M | -3.601M | -0.493M | -0.046M | 0.107M |
| Non Currrent Assets Other | 4.711M | 5.253M | 6.811M | 4.703M | 5.393M |
| Non Current Assets Total | 158.324M | 157.567M | 170.173M | 153.515M | 45.041M |
| Capital Lease Obligations | 36.536M | 43.946M | 26.378M | 26.135M | 29.081M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -94.099M | 118.168M | -46.489M | -153.404M | 18.317M |
| Total Cashflows From Investing Activities | - | 114.068M | -54.466M | -140.522M | 12.252M |
| Total Cash From Financing Activities | 118.039M | 1.284M | 282.106M | 224.122M | 131.824M |
| Net Income | -153.219M | -220.432M | -192.502M | -115.976M | -133.746M |
| Change In Cash | -17.87M | -61.997M | 63.837M | -96.243M | 103.407M |
| Begin Period Cash Flow | 141.522M | 207.396M | 143.559M | 239.802M | 136.395M |
| End Period Cash Flow | 123.652M | 145.399M | 207.396M | 143.559M | 239.802M |
| Total Cash From Operating Activities | -132.178M | -177.349M | -163.803M | -179.843M | -40.669M |
| Depreciation | 6.064M | 6.337M | 5.053M | 3.959M | 2.83M |
| Other Cashflows From Investing Activities | - | 0.018M | - | 20.044M | 0.102M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | -3.346M | -5.651M | 10.651M |
| Sale Purchase Of Stock | - | 1.284M | 282.106M | 224.122M | 131.824M |
| Other Cashflows From Financing Activities | 0.96M | 0.305M | 282.106M | 224.122M | 15.483M |
| Capital Expenditures | 4.719M | 4.118M | 7.977M | 7.162M | 6.167M |
| Change In Working Capital | -1.594M | 8.176M | -21.41M | -102.22M | 65.932M |
| Other Non Cash Items | -9.761M | -0.724M | 1.657M | 27.604M | -2.928M |
| Free Cash Flow | -136.897M | -181.467M | -171.78M | -187.005M | -46.836M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 1 year ago | 6256806 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 2503876 |
| 3. | Vanguard Small Cap Index | 1 year ago | 2077181 |
| 4. | iShares Russell 2000 ETF | 1 year ago | 1925687 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1288797 |
| 6. | Vanguard Small Cap Growth Index Inv | 1 year ago | 1173868 |
| 7. | Pictet Biopharmaceutical Mother | 1 year ago | 921000 |
| 8. | JPM Thematics Genetic Thrps C2 Acc USD | 1 year ago | 899790 |
| 9. | Fidelity Small Cap Index | 1 year ago | 840880 |
| 10. | Nuveen Quant Small Cap Equity R6 | 1 year ago | 769700 |
| 11. | iShares Russell 2000 Value ETF | 1 year ago | 764422 |
| 12. | CS (Lux) Digital Health Equity SB USD | 1 year ago | 750000 |
| 13. | Direxion Daily S&P Biotech Bull 3X ETF | 1 year ago | 629638 |
| 14. | iShares Biotechnology ETF | 1 year ago | 603892 |
| 15. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 508140 |
| 16. | Vanguard Strategic Equity Inv | 1 year ago | 486795 |
| 17. | Fidelity Extended Market Index | 1 year ago | 481316 |
| 18. | Dimensional US Targeted Value ETF | 1 year ago | 450725 |
| 19. | DFA US Targeted Value I | 1 year ago | 411496 |
| 20. | Selectra J. Lamarck Biotech A | 1 year ago | 409400 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 1 year ago | 8555597 |
| 2. | BlackRock Inc | 1 year ago | 7838969 |
| 3. | Deep Track Capital, LP | 1 year ago | 5527290 |
| 4. | State Street Corporation | 1 year ago | 5069543 |
| 5. | Dimensional Fund Advisors, Inc. | 1 year ago | 2607765 |
| 6. | Pictet Asset Manangement SA | 1 year ago | 2261645 |
| 7. | Millennium Management LLC | 1 year ago | 2236617 |
| 8. | Geode Capital Management, LLC | 1 year ago | 1901735 |
| 9. | Two Sigma Investments LLC | 1 year ago | 1387982 |
| 10. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1264535 |
| 11. | Two Sigma Advisers, LLC | 1 year ago | 1234300 |
| 12. | Goldman Sachs Group Inc | 1 year ago | 1108148 |
| 13. | D. E. Shaw & Co LP | 1 year ago | 1089240 |
| 14. | JPMorgan Chase & Co | 1 year ago | 1051007 |
| 15. | Credit Suisse First Boston (CSFB) | 1 year ago | 903257 |
| 16. | Squarepoint Ops LLC | 1 year ago | 898456 |
| 17. | Woodline Partners LP | 1 year ago | 895000 |
| 18. | Northern Trust Corp | 1 year ago | 869968 |
| 19. | Charles Schwab Investment Management Inc | 1 year ago | 856095 |
| 20. | Rafferty Asset Management, LLC | 1 year ago | 853114 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...